Innova Captab Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a significant 34.0% year-over-year growth in revenue from operations, reaching ₹470.9 crore. EBITDA also saw a substantial increase of 32.7%, amounting to ₹75.1 crore. Profit After Tax (PAT) grew by 42.3% to ₹44.1 crore, underscoring a strong start to the fiscal year.
Innova Captab Reports Strong Q1 FY27 Performance
Innova Captab Limited has delivered a robust performance in the first quarter of the fiscal year 2027, ending June 30, 2026. The company announced its unaudited consolidated financial results, highlighting significant year-over-year growth across key financial metrics.
Key Financial Highlights (Q1 FY27 vs. Q1 FY26)
The company’s Revenue from Operations surged by an impressive 34.0% to ₹470.9 crore, compared to ₹351.5 crore in the same period last year. This strong revenue growth was complemented by a 32.7% increase in EBITDA, which reached ₹75.1 crore from ₹56.6 crore in Q1 FY26. The EBITDA margin stood at 16.0%.
Furthermore, the Profit After Tax (PAT) for the quarter saw a substantial jump of 42.3%, totaling ₹44.1 crore, up from ₹31.0 crore in the prior year’s corresponding quarter. The PAT margin was reported at 9.4%.
Management Commentary
Commenting on the performance, Mr. Vinay Lohariwala, Managing Director of Innova Captab Limited, stated, “Innova Captab Limited delivered a strong start to FY27, with revenue and EBITDA growing by 34% and 33% YoY, respectively. The performance underscores the continued strength of our diversified business model, disciplined execution, and sustained customer traction across both our CDMO Services & Products and Branded Generics businesses.”
He further added that growth was driven by steady order flows, an expanded product portfolio, and deeper engagement with customers. The company’s focus on operational excellence and manufacturing efficiency is strengthening its competitive positioning. The Jammu facility is also witnessing a steady ramp-up, supported by increasing business from existing and new clients. Innova Captab remains committed to strengthening its CDMO partner position and expanding its branded generics footprint, with a clear strategic roadmap for sustained growth and profitability.
About Innova Captab Limited
Innova Captab Limited is a leading pharmaceutical company in India with a comprehensive business model covering research and development, manufacturing, drug distribution, marketing, and exports. The company operates a Contract Development and Manufacturing Organization (CDMO) business, serving over 350 clients in India and international markets, alongside its Branded Generics Business. Innova Captab operates five state-of-the-art manufacturing facilities accredited by leading global regulatory bodies.
Source: BSE
